FoRx Therapeutics is a clinical-stage biotechnology company focused on creating precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers. Its lead asset, FORX-428, is an orally available, proprietary small-molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG), a key DNA repair enzyme. Preclinical data show robust anti-tumor activity across multiple solid tumor types and a favorable safety profile, supporting its potential as both a monotherapy and in combination regimens. The company has progressed FORX-428 into Phase 1 clinical trials aimed at patients with advanced solid tumors possessing specific DDR deficiencies or high replication stress. Capital from recent financings is earmarked to advance this Phase 1 program and further IND-enabling studies. Investors include EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures, underscoring strong strategic support from both financial and pharma venture arms. While revenue has not yet been generated, the company’s pipeline and proprietary technology platform position it for future value inflection as clinical data mature. Operating from Basel, Switzerland, FoRx Therapeutics continues to strengthen its balance sheet to fuel clinical development and potential pipeline expansion.

Total raised

$61M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025